Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV

Severe fever with thrombocytopenia syndrome virus was first discovered in 2009 as the causative agent of severe fever with thrombocytopenia syndrome. Despite its potential threat to public health, no prophylactic vaccine is yet available. This study developed a heterologous prime-boost strategy comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jae-Yong, Jeon, Kyeongseok, Hong, Jung Joo, Park, Sang-In, Cho, Hyeonggon, Park, Hyo-Jung, Kwak, Hye Won, Park, Hyeong-Jun, Bang, Yoo-Jin, Lee, Yu-Sun, Bae, Seo-Hyeon, Kim, So-Hee, Hwang, Kyung-Ah, Jung, Dae-Im, Cho, Seong Hoo, Seo, Sang Hwan, Kim, Green, Oh, Hanseul, Lee, Hwal-Yong, Kim, Ki Hyun, Lim, Hee-Young, Jeon, Pyeonghwa, Lee, Joo-Yeon, Chung, Junho, Lee, Sang-Myeong, Ko, Hae Li, Song, Manki, Cho, Nam-Hyuk, Lee, Young-suk, Hong, So-Hee, Nam, Jae-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199661/
https://www.ncbi.nlm.nih.gov/pubmed/37210393
http://dx.doi.org/10.1038/s41598-023-35328-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199661/
https://www.ncbi.nlm.nih.gov/pubmed/37210393
http://dx.doi.org/10.1038/s41598-023-35328-9

Ejemplares similares